The USPSTF recommends screening all adults for depression, including pregnant and postpartum people and adults 65 or older (grade B, June 2023). It adds that screening needs systems for accurate diagnosis, effective treatment and follow-up. A workable primary care version is a PHQ-2 for every eligible patient, a PHQ-9 for positives, results in the chart before the clinician enters, and a documented plan for every positive screen.
What the guidelines and measures ask for
For adolescents aged 12 to 18, the USPSTF recommends screening for major depressive disorder (grade B, October 2022). Its evidence review identified no studies that used the PHQ-9 in this age group, so use a form validated for adolescents. For children 11 or younger, and for suicide risk screening at any age, the Task Force found the evidence insufficient.
The CMS quality measure Screening for Depression and Follow-Up Plan (CMS2) covers patients 12 and older. It counts a screen with an age-appropriate standardized tool on the date of the encounter or up to 14 days before. If the screen is positive, a follow-up plan must be documented on the date of the encounter or up to two days after. Build those two windows into the workflow, because a positive screen without a timely plan does not count.
Longer and clinician-rated scales serve other purposes, as the comparison of depression assessment tools explains.
Two-step screening: PHQ-2 first, PHQ-9 if positive
Step 1: PHQ-2 for everyone. The PHQ-2 asks how often the patient has had depressed mood and loss of interest over the past two weeks, scored 0-3 each. In a 2020 meta-analysis of studies using semistructured interviews, a PHQ-2 of 2 or more followed by a PHQ-9 of 10 or more identified 82% of interview-diagnosed major depression. The PHQ-9 alone identified 86%, and the sequence needed 57% fewer full PHQ-9s. With a PHQ-2 gate of 3, the sequence identified 70%. The cutoff, workload and billing trade-offs are laid out in two-step depression screening. Choose the cutoff in the practice protocol before screening begins.
Step 2: PHQ-9 for positive PHQ-2. The PHQ-9 adds a structured estimate of symptom severity and includes an item about thoughts of death or self-harm. It does not confirm depression.
Workflow implementation
Who screens? Options include medical assistants during rooming, tablets at check-in, paper in the waiting room, or an electronic questionnaire before the visit. A pre-visit screen completed up to 14 days before the encounter still meets the CMS2 screening window.
When to screen? The USPSTF found no evidence on the best screening frequency. Medicare pays for one annual depression screen in primary care settings with staff-assisted depression care supports, billed as G0444. Annual wellness and new-patient visits are two places to build it in. Set the interval in the practice protocol from the current guideline, measure specification and patient context.
Step-by-step:
- The EHR flags patients due for screening.
- During rooming, the MA asks the PHQ-2 questions or confirms the patient completed them.
- If the score is at or above the protocol cutoff (3, or 2 if your protocol uses it), the patient completes the PHQ-9.
- Results go into the EHR before the clinician enters.
- The clinician reviews results, with positive screens flagged.
- The clinician completes the assessment and documents a follow-up plan for any positive screen.
Sample script for staff: "I'm going to ask you two quick questions about your mood that we ask all our patients." If positive: "Based on those answers, I'd like you to complete a few more questions so we can better understand how you're doing."
Responding to positive screens
A positive screen isn't a diagnosis. It's the start of clinical assessment, and the total does not select a treatment or referral.
PHQ-9 scores 5-9 (mild): Record the mild symptom band. Review the item pattern, functioning, medical context, substance use, and life circumstances.
PHQ-9 scores 10-14 (moderate): Record the moderate symptom band. Use the interview to assess duration, impairment, differential diagnoses, and the patient's account.
PHQ-9 scores 15+ (moderately severe to severe): Record the applicable symptom band and complete the clinical assessment. The total alone cannot determine urgency, medication, psychotherapy, or referral.
Item 9 response: Any score above zero on item 9 needs same-day follow-up under the practice's safety protocol, regardless of the total. Ask directly about suicidal thoughts, distinguish passive thoughts from active plans, assess intent and access to means, and take the safety steps the protocol sets. Item 9 is a single question, not a suicide risk assessment.
If you need help now. In the US, Call 988 or text 988. Call 911 if you are in immediate danger. Outside the US, contact your local emergency number or find support in your country.
When to refer vs. manage in primary care
Refer to behavioral health when the patient prefers specialty care, symptoms are not improving with initial treatment, the presentation is complex, or suicidal ideation needs specialty assessment.
Manage in primary care when the presentation is straightforward, the patient prefers it, and the response to initial treatment is good. Collaborative care makes shared management possible. In that model, a care manager and a psychiatric consultant work with the primary care team. They track patients in a registry with validated rating scales and review the caseload weekly (CMS behavioral health integration booklet). Billing for those services is covered in two-step depression screening.
Follow-up and measurement-based care
For patients being monitored, choose a reassessment interval that fits the PHQ-9's two-week recall period, the care plan, and local protocol. Compare the same questionnaire over time, and review the answers alongside function and the clinical interview. Measurement-based care describes the evidence and the workflow for repeated measures.
- Record the raw total and item-level answers.
- Describe the direction and size of a score change without assigning a cause.
- Do not use a total alone to declare response or remission.
In a study of 434 older adults in the IMPACT trial, a five-point PHQ-9 difference was the estimated minimum clinically important change. Treat a change of that size as a reason to review, not as a universal response rule. Tracking PHQ-9 scores over time covers comparing results.
If the score pattern and clinical picture do not align: Reassess the diagnosis, adherence, comorbid conditions, functioning, and treatment context. Base any change in care on that fuller review.
When patients decline treatment: Document that you discussed results and options, note their reasons if provided, and offer rescreening at a future visit.
Common implementation challenges
"We don't have time." A pre-visit electronic screen uses no visit time, and the PHQ-2 adds two questions to rooming. Positive screens justify the additional time.
"Too many false positives." The PHQ-2 is a gate, not a diagnosis. In the 2020 meta-analysis, a PHQ-2 of 2 or more alone had 67% specificity. Adding the PHQ-9 step raised it to 87%. Clinical assessment, not the screen, decides what happens next.
"Patients resist the questions." Frame screening as routine: "we ask everyone." Explain who sees the answers and what happens next.
"I'm not trained to treat depression." The USPSTF ties screening to systems for diagnosis, treatment and follow-up. Set up the referral pathway or collaborative care arrangement before screening starts, so every positive screen has somewhere to go.
Measuring success
Process measures: Screening rate, timeliness of follow-up for positive screens, and documentation completeness. The CMS2 measure combines the first two.
Outcome measures: Detection rate, treatment initiation rate for positive screens, PHQ-9 score change over time, and referral completion rates.
Review the metrics regularly. Check the screening rate, whether positive screens are getting follow-up, and where patients drop out of the process.
